XyloCor Therapeutics: Funding, Investors & Team (Oct 2026)
XyloCor Therapeutics is a biotechnology company that specializes in developing gene therapies for patients with severe coronary artery disease. Their primary focus is on their leading candidate, XC001, which is currently in clinical trials for patients with refractory angina, targeting important medical needs. By working with Weill Cornell Medical College, the company aims to enhance patient outcomes using groundbreaking gene therapy technologies.
XyloCor Therapeutics has raised $90.1M across 2 funding rounds on record, the most recent a Series B of $67.5M announced in Jan 2025.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
XyloCor Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2025.
XyloCor Therapeutics Funding Rounds
XyloCor Therapeutics raised $22.6M in a Series A announced in Mar 2021.
3.8 years later, a Series B of $67.5M was announced in Jan 2025.
XyloCor Therapeutics Founders and Leadership Team
Contact details for the XyloCor Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →XyloCor Therapeutics Funding Compared to Other Biotechnology Startups
XyloCor Therapeutics' latest round of $67.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like XyloCor Therapeutics in Biotechnology and Wayne
Companies Similar to XyloCor Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
XyloCor Therapeutics Funding FAQs
What does XyloCor Therapeutics do?
XyloCor Therapeutics is a biotechnology company that specializes in developing gene therapies for patients with severe coronary artery disease. Their primary focus is on their leading candidate, XC001, which is currently in clinical trials for patients with refractory angina, targeting important medical needs. By working with Weill Cornell Medical College, the company aims to enhance patient outcomes using groundbreaking gene therapy technologies.
How much funding has XyloCor Therapeutics raised?
XyloCor Therapeutics has raised $90.1M across 2 rounds on record. The most recent is a Series B of $67.5M announced in Jan 2025.
When did XyloCor Therapeutics last raise funding?
XyloCor Therapeutics' most recent funding round on record is a Series B of $67.5M, announced in Jan 2025.
Who founded XyloCor Therapeutics?
FundedIQ lists Ronald G Crystal (Founder) at XyloCor Therapeutics.
Who is the CEO of XyloCor Therapeutics?
Al Gianchetti is listed as CEO at XyloCor Therapeutics.
Where is XyloCor Therapeutics headquartered?
XyloCor Therapeutics is based in Wayne, Pennsylvania, United States.
How many employees does XyloCor Therapeutics have?
XyloCor Therapeutics is in the 11-50 employee band.
How does XyloCor Therapeutics' funding compare to other Biotechnology startups?
XyloCor Therapeutics' latest round of $67.5M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's XyloCor Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for XyloCor Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.